Executive Summary
Alvio Labs currently operates as a pre-revenue startup with significant funding dependency. Q1 2026 shows a net loss of -€4,226.52 with zero recorded revenue and €116.00 in cash reserves. At the current monthly burn rate of ~€1,691, operational runway is critically limited to approximately 2 days without additional capital injection.
The business is funded entirely through director facilities: €23,697.62 in current account drawings and €12,550.00 in formal loans totaling €36,247.62 in related-party obligations. Total liabilities have grown +141% year-over-year. Immediate priority: revenue generation or additional funding required.
~2 days remaining
per month (Q1 average)
Revolut EUR Main
Jan 1 - Mar 18, 2026
Profit & Loss
Q1 2026 Breakdown
| Account | Amount (€) | % of Total |
|---|---|---|
| Cost of Goods Sold | 3,032.07 | 71.7% |
| Consulting & Accounting | 613.00 | 14.5% |
| Office : Software | 271.65 | 6.4% |
| Research & Development | 191.98 | 4.5% |
| Office Expenses | 53.47 | 1.3% |
| Subscriptions | 42.36 | 1.0% |
| Travel - National | 20.00 | 0.5% |
| Bank Fees | 1.99 | 0.1% |
| Net Profit / Loss | -4,226.52 | 100% |
Analyst Note: COGS at 71.7% of net loss suggests product-related investments. Consulting (14.5%) indicates professional services engagement — typical for early-stage setup.
Balance Sheet Evolution
YoY Comparison (Mar 2025 vs Mar 2026)
Balance Sheet
vs €532.14 (Mar 2025)
vs €14,948.99 (Mar 2025)
-149% change YoY
Director Funding
Key Ratios
* Ratios calculated on Q1 actuals (no revenue base)
Working Capital
Required Actions
Secure Immediate Funding
Cash reserves will deplete within 48 hours. Inject capital or accelerate revenue.
Record Revenue Transactions
Q1 shows zero revenue. Ensure all sales are recorded in Xero.
Director Loan Documentation
€36K in related-party debt. Ensure proper loan agreements and interest terms.